Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria

Kamusheva, Maria; Vandeva, Silvia; Mitov, Konstantin; Parvanova, Alexina; Pesheva, Marina; Ganov, Nikolay; Rusenova, Yanitsa; Marinov, Lyubomir; Getova, Violeta; Еленкова, Атанаска; Petrova, Guenka

doi:10.3390/pharmaceutics15020438

Cited by 6 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More researchers have realized that evaluating memory, attention, language, and executive functions is intriguing and crucial from the QoL perspective [ 12 , 13 ]. A new study shows that patients’ quality of life and the duration of the disease affect their medication adherence [ 14 ]. Meanwhile, the methods of magnetic resonance imaging (MRI) and neurophysiological imaging were employed to find evidence of brain changes in acromegalic patients.…”

Section: Historical Perspectivementioning

confidence: 99%

Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly

Chen

Xiang

Zhang

et al. 2023

JCM

View full text Add to dashboard Cite

Acromegaly is a chronic disease caused by the overproduction of growth hormone (GH) and accompanying insulin-like growth factor-1 (IGF-1), which is often caused by GH-secreting pituitary adenomas. In addition to its somatic burden, a growing number of studies have found that patients suffering from acromegaly exhibit psychosocial and personality changes. Over the past 70 years, there has been increasing interest in the cognitive impairment and neuropsychological issues of patients with acromegaly, and a variety of neuropsychological and neurophysiological tests have been used to measure cognitive changes in patients. The impact of disease progression status, treatment modalities, and various comorbidities on cognitive function and the mechanisms of cognitive impairment in patients with acromegaly are therefore outlined in this review. Multidisciplinary assessment has important implications for the management of acromegaly, particularly in relation to cognitive function. Here, we summarize the relevant literature concerning cognitive-behavioral research on acromegaly to demonstrate the impact of long-term impairment caused by GH and IGF-1 on the cognitive behavior of patients.

show abstract

Section: Historical Perspectivementioning

confidence: 99%

Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly

Chen

Xiang

Zhang

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Acromegaly is a rare neuroendocrinological disorder characterized by over-secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels ( 1 , 2 ). The majority of GH-secreting pituitary tumors are benign, although some tumors may present with aggressive features and have a high risk of recurrence after surgical treatment ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Using 2-dimensional hand photographs to predict postoperative biochemical remission in acromegaly patients: a transfer learning approach

Wang¹,

Duan²,

Yao³

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background The primary treatment goals in acromegaly patients are complete surgical removal of underlying pituitary tumors and biochemical remission. One of the challenges in developing countries is the difficulty in monitoring postoperative biochemical levels in acromegaly patients, particularly those who live in remote areas or regions with limited medical resources. Methods In an attempt to overcome the abovementioned challenges, we conducted a retrospective study and established a mobile and low-cost method to predict biochemical remission in acromegaly patients after surgery, the efficacy of which was assessed retrospectively using the China Acromegaly Patient Association (CAPA) database. A total of 368 surgical patients from the CAPA database were successfully followed up to obtain their hand photographs. Demographics, baseline clinical characteristics, pituitary tumor features, and treatment details were collated. Postoperative outcome, defined as biochemical remission at the last follow-up timepoint, was assessed. Transfer learning with a new mobile tailored neurocomputing architecture, MobileNetv2, was used to explore the identical features that could be used as predictors of long-term biochemical remission after surgery. Results As expected, the MobileNetv2-based transfer learning algorithm was shown to predict biochemical remission with statistical accuracies of 0.96 and 0.76 in the training cohort (n=803) and validation cohort (n=200), respectively, and the loss function value was 0.82. Conclusions Our findings demonstrate the potential of the MobileNetv2-based transfer learning algorithm in predicting biochemical remission for postoperative patients who are at home or live far away from a pituitary or neuroendocrinological treatment center.

show abstract

Exploring potential influencing factors of inadherence to specialist aftercare and long-term medication in patients with acromegaly

Siegel,

Giese,

Honegger

et al. 2024

Pituitary

View full text Add to dashboard Cite

Purpose To improve the understanding of adherence as one major factor of disease control in acromegaly patients, we systematically assessed patients’ motivations to adhere to advised follow-up schedules and recommended medication for acromegaly. Methods Cross-sectional, postal questionnaire study on adult patients with acromegaly, operated upon a growth hormone producing pituitary adenoma more than 1 year ago in two tertiary treatment centers. We assessed demographic and clinical characteristics, disease status, adherence to acromegaly medication and/or aftercare, and the five dimensions defined by the World Health Organization influencing adherence. Wherever applicable, we included validated short scales. The answers of 63 patients (33 f, 30 m; mean age 56.1 y) were analyzed. Results Patients with problems in adherence to aftercare had a significantly lower subjective symptomload than those adherent to aftercare (p = 0.026) and a lower perceived need for treatment (p = 0.045). Patients with adherence problems to medication had a higher subjective symptomload than those without (p = 0.056). They also tended to have shorter consultations, were significantly more often dissatisfied with the duration of their medical consultations (42% vs 4.8%, p = 0.019) and tended to find that their physician explained potential difficulties with adherence less well than patients without adherence problems (p = 0.089). Conclusions To our knowledge, this is the first study which explored adherence to medication and aftercare in patients with acromegaly, taking into account potential influencing factors from all areas defined by the WHO model of adherence. Of the modifiable factors of adherence, patient–doctor relationship seemed to play a crucial role and could be one leverage point to improve adherence.

show abstract

Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria

Cited by 6 publications

References 34 publications

Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly

Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly

Using 2-dimensional hand photographs to predict postoperative biochemical remission in acromegaly patients: a transfer learning approach

Exploring potential influencing factors of inadherence to specialist aftercare and long-term medication in patients with acromegaly

Contact Info

Product

Resources

About